ClinicalTrials.gg
CompletedNCT00620555Updated Feb 3, 2021Results posted

A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures

A Phase 3 interventional study of gabapentin in Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 22 sites in Japan. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2021-02-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Epilepsies, Partial by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Epilepsies, Partial · Viatris Inc..

Enrollment
11th of 13
65 · median 136
Started
2008
with 3 others
Phase 3
8 of 15
none open now
Registered
12th of 15
by date

Among the 15 studies in Epilepsies, Partial by Viatris Inc., this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2008, is one of 8 in phase 3, and was the 12th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 15 studies in Epilepsies, Partial by Viatris Inc. is open now. The open studies under Epilepsies, Partial, anywhere →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Epilepsies, Partial by Viatris Inc. as a file.
02

Study summary

Examine the safety and efficacy of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures

03

Conditions studied

  • Epilepsies, Partial

Browse trials for

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of study A9451162 (NCT00603473)

Exclusion criteria

Exclusion Criteria:

  • Seizures related to drugs or acute medical illness
  • History of any serious medical or psychiatric disorder
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    gabapentin

    Drug: gabapentin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)

    Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. Severe AEs: those which interferes significantly with participant's usual function. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.

    Time frame: up to 53 weeks

Secondary outcomes

  1. Response Ratio

    The Response Ratio calculated by the following equation : Response Ratio = (T minus B) divided by (T plus B), where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).

    Time frame: Up to 52 weeks

  2. Responder Rate

    Responder Rate was defined as the percentage of subjects with a 50 percent or greater reduction in the seizure frequency per 28 days for the 52-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period of the previous study A9451162 (NCT00603473).

    Time frame: Up to 52 weeks

  3. Percent Change in Seizure Frequency

    Percent change in seizure frequency (PCH) was calculated as follows: PCH = 100\*(T minus B) divided by B, where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).

    Time frame: Up to 52 weeks

07

Results

Posted Dec 20, 2011

Participant flow

Participant flow — Overall Study
MilestoneGabapentin
Started65
Completed44
Not completed21
Withdrew: Adverse event4
Withdrew: Protocol violation2
Withdrew: Lack of efficacy12
Withdrew: Withdrawal by subject1
Withdrew: Choice of other treatment1
Withdrew: Visit failure against planned1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)

Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. Severe AEs: those which interferes significantly with participant's usual function. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.

Time frame:
up to 53 weeks
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)
ParticipantsGabapentin
All-causality adverse events (AEs)58
Treatment-related AEs13
All-causality serious AEs2
Treatment-related serious AEs0
All-causality severe AEs1
Treatment-related severe AEs0
Discontinuation due to all-causality AEs4
Discontinuation due to treatment-related AEs2
Dose reduction due to all-causality AEs2
Dose reduction due to treatment-related AEs2
SecondaryResponse Ratio

The Response Ratio calculated by the following equation : Response Ratio = (T minus B) divided by (T plus B), where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).

Time frame:
Up to 52 weeks
Reported as:
Mean · Ratio
Response Ratio
RatioGabapentin
Week 1 to 8 (n=65)-0.263 ± 0.3141
Week 9 to 16 (n=60)-0.256 ± 0.3513
Week 17 to 24 (n=58)-0.300 ± 0.3671
Week 25 to 36 (n=54)-0.280 ± 0.3753
Week 37 to 52 (n=47)-0.327 ± 0.3712
SecondaryResponder Rate

Responder Rate was defined as the percentage of subjects with a 50 percent or greater reduction in the seizure frequency per 28 days for the 52-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period of the previous study A9451162 (NCT00603473).

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Responder Rate
Percentage of participantsGabapentin
Week 1 to 8 (n=65)35.4 (23.9 to 48.2)
Week 9 to 16 (n=60)40.0 (27.6 to 53.5)
Week 17 to 24 (n=58)39.7 (27.1 to 53.4)
Week 25 to 36 (n=54)40.7 (27.6 to 55.0)
Week 37 to 52 (n=47)46.8 (32.1 to 61.9)
SecondaryPercent Change in Seizure Frequency

Percent change in seizure frequency (PCH) was calculated as follows: PCH = 100\*(T minus B) divided by B, where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).

Time frame:
Up to 52 weeks
Reported as:
Median · Percent change
Percent Change in Seizure Frequency
Percent changeGabapentin
Week 1 to 8 (n=65)-34.2 (-100.0 to 63.1)
Week 9 to 16 (n=60)-33.0 (-100.0 to 99.8)
Week 17 to 24 (n=58)-42.0 (-100.0 to 112.5)
Week 25 to 36 (n=54)-41.6 (-100.0 to 110.7)
Week 37 to 52 (n=47)-49.2 (-100.0 to 131.7)

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gabapentin—2/65 (3.1%)48/65 (73.8%)
Most frequent serious events
Most frequent serious events
EventGabapentin
BRONCHOPNEUMONIARespiratory, thoracic and mediastinal disorders1/65
ENCEPHALOPATHYNervous system disorders1/65
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGabapentin
NasopharyngitisInfections and infestations28/65
SomnolenceNervous system disorders10/65
InfluenzaInfections and infestations9/65
PyrexiaGeneral disorders8/65
DiarrhoeaGastrointestinal disorders7/65
Dental cariesGastrointestinal disorders5/65
VomitingGastrointestinal disorders4/65
BronchitisInfections and infestations4/65
PharyngitisInfections and infestations4/65
Upper respiratory tract infectionInfections and infestations4/65

Baseline characteristics

Age, Customized
Age, Customized(Participants)Gabapentin
3-4 years8
5-12 years42
13-16 years15
Sex: Female, Male
Sex: Female, Male(Participants)Gabapentin
Female27
Male38
08

Study locations

22 sites
  • Pfizer Investigational Site
    Obu-shi,Morioka-machi, Aichi, Japan
  • Pfizer Investigational Site
    Jonan-ku, Fukuoka, Japan
  • Pfizer Investigational Site
    Kobe, Hyogo, Japan
  • Pfizer Investigational Site
    Suma-Ku,Kobe, Hyogo, Japan
  • Pfizer Investigational Site
    Kanazawa, Ishikawa, Japan
  • Pfizer Investigational Site
    Zentsuuji, Kagawa, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa Pref., Japan
  • Pfizer Investigational Site
    Sendai-shi, Miyagi-ken, Japan
  • Pfizer Investigational Site
    Showa-Ku, Nagoya, Japan
  • Pfizer Investigational Site
    Niigata-shi, Niigata, Japan
  • Pfizer Investigational Site
    Kurashiki-City, Okayama Pref., Japan
  • Pfizer Investigational Site
    Okayama-shi, Okayama, Japan
  • Pfizer Investigational Site
    Izumi-shi, Osaka, Japan
  • Pfizer Investigational Site
    Miyakojima-ku, Osaka, Japan
  • Pfizer Investigational Site
    Suita, Osaka, Japan
  • Pfizer Investigational Site
    Shizuoka-shi, Shizuoka, Japan
  • Pfizer Investigational Site
    Kodaira, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinjuku-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Hiroshima, Japan
  • Pfizer Investigational Site
    Saitama, Japan
  • Pfizer Investigational Site
    Yamagata, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2008
First posted
Feb 21, 2008
Start
May 2008
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Dec 20, 2011
Last update
Feb 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00620555
Responsible party
Sponsor
First posted
Feb 21, 2008
Start date
May 2008
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Dec 20, 2011
Last update
Feb 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion